Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
If a research model involves multiple organ failure, severe gut damage, or a tendon that refuses to heal due to poor blood supply, BPC-157 is the superior choice
The most common adverse effects are mild injection-site reactions and rare transient flushing
Heres what the clinical evidence shows: Study Scope: 900+ participants across 6 randomized, double-blind, placebo-controlled trials Safety Profile: Indistinguishable from placebo in tolerability assessments Serious Events: Zero serious adverse events attributed to AOD-9604 Withdrawals: No treatment-related discontinuations in any trial Common Effects: Mild headache and minor GI symptoms at rates similar to placebo IGF-1 Impact: No effect on insulin-like growth factor-1 levels Metabolic Safety: No negative impact on glucose metabolism or insulin sensitivity Immunogenicity: Zero participants developed anti-AOD9604 antibodies The following analysis provides complete details on the clinical trial evidence supporting AOD-9604s favorable safety profile
A standard glow peptide formulation contains GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), BPC-157 (body protection compound-157), and TB-500 (thymosin beta-4 fragment)
Verify current product details on supplier website
